Exploring MSC and HSPC interactions: new frontiers in hematopoiesis and transplant medicine
Suresh S., Venkatesan V., Thangavel S., Marepally S.
Narrative Review, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Stem Cell Res Ther (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41250227
- PMCID
- PMC12625565
- DOI
- 10.1186/s13287-025-04753-0
- Citations
- 4
Abstract (original English)
Mesenchymal stromal cells (MSCs) play a critical role in supporting hematopoietic stem and progenitor cells (HSPCs) within the bone marrow (BM) niche by providing a specialized extracellular matrix and essential signaling cues. Through the secretion of key ECM proteins and cell adhesion molecules, MSCs regulate HSPC proliferation, differentiation, homing, retention, and maintain their quiescence necessary for effective hematopoiesis. Understanding the intricate dynamics between MSCs and HSPCs in the BM is essential for advancing HSPC-based therapies. Targeting niche components, such as ECM proteins and CAMs, can enable HSPC expansion and engraftment, benefiting hematopoietic stem cell transplantation and gene therapy outcomes. In this review, we provide an overview of the niche components involved in MSCs-HSPCs interactions and its co-culture in improving the therapeutic outcomes, discuss existing challenges and propose possible solutions.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.